Project Grant R44HL140680

Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...

Federal Project Grant Award Summary Airalux Medical, Inc. received a $306,872 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for September 4, 2026. The award supports development and commercialization of a digital incentive spirometer device designed to improve patient adherence to post-surgical respiratory therapy and streamline clinical...

The National Heart, Lung, and Blood Institute (NHLBI) awarded UCLA a $534,761 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop magnetoelastic vascular grafts (MVGs) as an innovative platform technology for continuous stenosis monitoring. The MVG research aims to address a critical clinical need, as approximately 40% of the 3 million vascular grafts implanted annually experience reduced patency within two years. The project, running from September 1,...

Grant Award Summary Heartpoint Global Inc. received a $1.77M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The funding supports the development and preparation for first-in-human clinical testing of the INTELLISTENT system, a minimally invasive, adjustable pulmonary flow restrictor designed to treat pediatric and congenital heart disease (CHD)...

Federal Project Grant Summary SafeBVM Corp. received a $499,932 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 17, 2025, and completion date of August 31, 2026. The grant funds the integration of SafeBVM's SOTAIR device with capnography sensor technology to standardize manual ventilation techniques and improve patient outcomes in emergency and critical care...

Starlight Cardiovascular, Inc. was awarded a $1,477,713 Project Grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program to develop the first FDA-approved stent designed specifically for ductus arteriosus. The ductus arteriosus is a natural blood vessel that remains open in infants born with certain congenital heart defects; currently there are no stents approved for this use, forcing clinicians to repurpose adult coronary stents which have a high 47%...

Federal Grant Award Summary Aptus, LLC received a $965,037 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The award supports the development and preclinical testing of an expandable pediatric pulmonary heart valve designed to address the critical clinical need for a growth-accommodating valve solution for infants and children born with severe heart...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a three-year Project Grant totaling $301,840 to The Regents of the University of California, San Francisco under the Cardiovascular Diseases Research program (CFDA 93.837) for the EPIC-LT (Eliminating PGD Through Inhibition of CCR5 in Lung Transplantation) initiative, effective August 1, 2025 through July 31, 2028. This project addresses primary graft dysfunction (PGD), which occurs in approximately...

Federal Project Grant Award Summary Georgia Tech Research Corporation received a $709,172 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2030. The award supports the development and validation of improved three-dimensional (3D) printed airway splints designed to treat tracheobronchomalacia (TBM), a congenital or acquired airway condition causing dynamic airway...

This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...